Physician profile
Robert J Smith
NPI 1477594901
$80,278.91
in general payments reported to CMS, 2019-2025
8 companies · $4,119 in 2025
The $4,119 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,484 · 2021: $11K · 2022: $8,550 · 2023: $14K · 2024: $11K · 2025: $4,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,064.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20,839.01 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $15,127.29 | 2024-2025 | |
| Eli Lilly and Company | $10,500.00 | 2021 | |
| Ipsen Bioscience INC. | $8,550.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,446.71 | 2019 | |
| Hra Pharma | $7,000.00 | 2023 | |
| Amarin Pharma, INC. | $6,351.90 | 2019 | |
| Roche Diabetes Care Gmbh | $3,464.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.